ZYME Zymeworks Inc
Price (delayed)
$15.01
Market cap
$1.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
$931.71M
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
Highlights
The company's debt fell by 23% YoY
Zymeworks's net income has shrunk by 155% YoY
ZYME's EPS has dropped by 146% year-on-year
Key stats
What are the main financial stats of ZYME
Market
Valuations
Earnings
Shares outstanding
68.88M
Market cap
$1.03B
Enterprise value
$931.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.91
Price to sales (P/S)
18.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.98
Revenue
$62.2M
Gross profit
$62.2M
Operating income
-$138.31M
Net income
-$113.67M
EBIT
-$118.02M
EBITDA
-$107.17M
Free cash flow
-$56.62M
Per share
Balance sheet
Liquidity
EPS
-$1.49
EPS diluted
-$1.49
Free cash flow per share
-$0.74
Book value per share
$5.17
Revenue per share
$0.82
TBVPS
$6.16
Total assets
$487.15M
Total liabilities
$120.17M
Debt
$20.22M
Equity
$366.98M
Working capital
$259.86M
Debt to equity
0.06
Current ratio
4.1
Quick ratio
3.82
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-172.3%
Gross margin
100%
Net margin
-182.8%
Operating margin
-222.4%
Return on assets
-21.3%
Return on equity
-27.1%
Return on invested capital
-32.9%
Return on capital employed
-29.3%
Return on sales
-189.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYME stock price
How has the Zymeworks stock price performed over time
Intraday
2.67%
1 week
5.11%
1 month
10.21%
1 year
31.55%
YTD
2.53%
QTD
2.53%
Financial performance
How have Zymeworks's revenue and profit performed over time
Revenue
$62.2M
Gross profit
$62.2M
Operating income
-$138.31M
Net income
-$113.67M
Gross margin
100%
Net margin
-182.8%
ZYME's operating income has dropped by 168% year-on-year
Zymeworks's net income has shrunk by 155% YoY
Zymeworks's gross profit has shrunk by 87% YoY
Zymeworks's revenue has plunged by 87% YoY
Growth
What is Zymeworks's growth rate over time
Valuation
What is Zymeworks stock price valuation
P/E
N/A
P/B
2.91
P/S
18.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.98
ZYME's EPS has dropped by 146% year-on-year
ZYME's P/B is 62% above its last 4 quarters average of 1.8 and 12% above its 5-year quarterly average of 2.6
The company's equity fell by 14% YoY and by 10% QoQ
Zymeworks's revenue has plunged by 87% YoY
The stock's price to sales (P/S) is 44% more than its last 4 quarters average of 12.8 but 43% less than its 5-year quarterly average of 32.3
Efficiency
How efficient is Zymeworks business performance
Zymeworks's ROA has plunged by 162% YoY and by 4.4% from the previous quarter
Zymeworks's return on equity has shrunk by 161% YoY and by 4.2% QoQ
ZYME's ROIC has dropped by 148% year-on-year and by 10% since the previous quarter
ZYME's ROS is down by 2.6% since the previous quarter
Dividends
What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZYME.
Financial health
How did Zymeworks financials performed over time
The company's current ratio fell by 42% QoQ and by 20% YoY
The quick ratio has declined by 42% since the previous quarter and by 23% year-on-year
The company's debt is 94% lower than its equity
The company's debt fell by 23% YoY
The debt to equity is up by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.